Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
暂无分享，去创建一个
B. Tran | R. Hicks | M. Hofman | J. Violet | T. Akhurst | J. Ferdinandus | S. Thang | A. Iravani | G. Kong | P. Eu | P. Jackson | S. Sandhu | A. Kumar | J. Mooi | C. Guo | S. Williams | M. Scalzo